金吾财讯 | 先声药业(02096)公告公布,于2025年12月3日,集团与旺山旺水(02630),就氢溴酸氘瑞米德韦新适应症订立许可协议。据该协议,集团将获得氢溴酸氘瑞米德韦在大中华区,于抗呼吸道合胞病毒(“RSV”)感染以及抗人偏肺病毒(HMPV)感染适应症的独家权益。
金吾财讯 | 先声药业(02096)公告公布,于2025年12月3日,集团与旺山旺水(02630),就氢溴酸氘瑞米德韦新适应症订立许可协议。据该协议,集团将获得氢溴酸氘瑞米德韦在大中华区,于抗呼吸道合胞病毒(“RSV”)感染以及抗人偏肺病毒(HMPV)感染适应症的独家权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.